Zoetis’ (ZTS) Buy Rating Reaffirmed at Cantor Fitzgerald
Zoetis Inc. (NYSE:ZTS)‘s stock had its “buy” rating reissued by equities research analysts at Cantor Fitzgerald in a note issued to investors on Wednesday. They currently have a $75.00 price objective on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 18.73% from the company’s current price.
Several other brokerages have also commented on ZTS. Jefferies Group LLC boosted their price objective on Zoetis from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, May 9th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $65.00 target price on shares of Zoetis in a research note on Friday, September 1st. Argus reaffirmed a “buy” rating and issued a $69.00 target price (up previously from $60.00) on shares of Zoetis in a research note on Tuesday, May 30th. CL King started coverage on Zoetis in a research note on Friday, May 26th. They issued a “buy” rating and a $71.00 target price for the company. Finally, Deutsche Bank AG reaffirmed a “buy” rating and issued a $65.00 target price (up previously from $62.00) on shares of Zoetis in a research note on Monday, July 17th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $65.44.
Zoetis (ZTS) traded up 0.52% on Wednesday, hitting $63.50. 1,223,538 shares of the stock were exchanged. Zoetis has a 52-week low of $46.86 and a 52-week high of $63.85. The company has a 50-day moving average price of $61.72 and a 200-day moving average price of $58.85. The firm has a market cap of $31.06 billion, a PE ratio of 35.90 and a beta of 1.02.
Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.53. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The company had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.27 billion. During the same quarter in the previous year, the firm earned $0.49 earnings per share. Zoetis’s revenue was up 5.0% on a year-over-year basis. On average, equities research analysts anticipate that Zoetis will post $2.34 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/06/zoetis-zts-buy-rating-reaffirmed-at-cantor-fitzgerald.html.
A number of hedge funds have recently made changes to their positions in the business. Gladstone Capital Management LLP bought a new position in shares of Zoetis during the second quarter valued at approximately $3,134,000. Harbour Capital Advisors LLC raised its holdings in shares of Zoetis by 19.8% during the first quarter. Harbour Capital Advisors LLC now owns 20,005 shares of the company’s stock valued at $1,068,000 after acquiring an additional 3,300 shares in the last quarter. Hermes Investment Management Ltd. raised its holdings in shares of Zoetis by 80.3% during the second quarter. Hermes Investment Management Ltd. now owns 236,350 shares of the company’s stock valued at $14,744,000 after acquiring an additional 105,276 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Zoetis by 21.1% during the first quarter. Ameriprise Financial Inc. now owns 1,614,416 shares of the company’s stock valued at $86,167,000 after acquiring an additional 281,139 shares in the last quarter. Finally, US Bancorp DE raised its holdings in shares of Zoetis by 35.0% during the second quarter. US Bancorp DE now owns 110,687 shares of the company’s stock valued at $6,905,000 after acquiring an additional 28,678 shares in the last quarter. Hedge funds and other institutional investors own 93.31% of the company’s stock.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.